17
Apr
2024

Genovior Biotech Corporation

Exhibitor at CPHI Japan 2024 stand 5N-16
About Us

Business: CDMO, CMO, Technology Transfer,  license-out  Materials: API (Oncology, & Peptide), Lyophilization vial products, Solution-vial, Cartridge, Pre-filled syringe
Type: Oncology, Peptide, Finished Drug Injectable Product.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • TW
  • 2016
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
View company profile
Contact info
  • 88637580280
  • Website
  • 4F No. 50-8 Keyan RD , Zhunan Township , 35053, Miaoll County , Taiwan, China
Show contact info Hide contact info
Event information
CPHI Japan 2024
  • 17 Apr 2024 – 19 Apr 2024
  • East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan
  • Visit us at stand 5N-16

Products Featured at CPHI Japan 2024

  • GBC Production Plant site Video

    Product GBC Production Plant site Video

    Genovior Biotechnology Corporation facility capabilities & current ongoing production lines
  • Semaglutide, Liraglutide (GLP-1 RAs)

    Product Semaglutide, Liraglutide (GLP-1 RAs)

    API
  • CDMO/CMO

    Product CDMO/CMO

    Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

    Our services include:

    1. Process Development
    2. Formulation Development
    3. Analytical Development
    ...
  • CDMO/CMO 1

    Product CDMO/CMO 1

    PFS, Lyophilization
  • CDMO/CMO 2

    Product CDMO/CMO 2

    PROTEIN, INJECTABLE
  • CDMO/CMO 3

    Product CDMO/CMO 3

    Biologic, Oncology
  • Dedicated Oncology Production

    Product Dedicated Oncology Production

    Genovior biotech corporation offers services which includes oncology production services. It provides api: process development and production, injectables: formulation development and production of lyophilization and liquid vials, packaging and labeling. Contact us for more information.
  • Formulation Development

    Product Formulation Development

    1.  Pre-formulation development

    2.  Long-acting release delivery system formulation development

    3.  Formulation development

  • Injectables Available for Licensing

    Product Injectables Available for Licensing

    Oncology-Azacitidine, Bortezomib, Gemcitabine, Pemetrexed, Fulvestrant    Peptide-Teriparatide, Glucagon, Octreotide Acetate, Terlipressin Acetate,Biologic,  Others
  • Interview by Newsweek, time to talk

    Product Interview by Newsweek, time to talk

    Interviewee：Dr. Steve J.P. Hsu (President of Genovior Biotech)
  • out licensing and supply

    Product out licensing and supply

    ( * Manufacturing of API for in-house use)ONCOLOGY
    Azacitidine*
    Bortezomib*
    Bendamustine*
    Carboplatin
    Carfilzomib*
    Docetaxel
    Epriubicin
    Fulvestrant*
    ...
  • PIPELINE AVAILABLE FOR OUR LICENSING AND SUPPLY

    Product PIPELINE AVAILABLE FOR OUR LICENSING AND SUPPLY

    Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

    Our services include:
    1. Process Development
    2. Formulation Development
    3. Analytical Deve...
  • Process Development

    Product Process Development

    1.  Upstream process development

    2.  Downstream process development

    3.  Peptide APIs synthesis platform

    4.  Small molecule drugs synthesis platform  

  • Regulatory Affairs

    Product Regulatory Affairs

    Global regulatory support 
  • Small Scale Biologics / Injectable Production

    Product Small Scale Biologics / Injectable Production

    1. 300L Fermenters x 2 lines

    2. Downstreams process

    3. 3,000L fermenters (2018)

Genovior Biotech Corporation Resources (1)